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ABSTRACT
Chronic hypertension has long been known to cause left ventricular remodeling.
Although previous studies pointed towards inflammation as the pathological driver of cardiac
remodeling, the exact mechanistic pathway associated with pressure overload-induced cardiac
remodeling remains to be elucidated. In order to address this issue, we designed this study to
determine pathways associated with pressure overload induced cardiac remodeling and identify
therapeutic targets to attenuate this maladaptive cardiac remodeling. Rats with surgically
constricted abdominal aorta were used as an animal model for pressure overload and associated
Left ventricular (LV) structure and functional changes were measured by pressure-volume
admittance catheterization. Human cardiac fibroblasts were used to assess the specific
mechanistic pathways associated with prostaglandin D2 (PGD2) mediated fibrotic response. At
the 14 day period, pressure overloaded animals showed significant changes in LV structural and
functional parameters. Cyclooxygenase-2 (COX-2) inhibition with Nimesulide significantly
attenuated the structural and functional changes associated with LV remodeling due to pressure
overload. Prevention treatment with Nimesulide showed that the beneficial effects seen with
acute treatment were still prevalent even after discontinuation of treatment. Intervention
treatment with Nimesulide showed that only a few parameters like chamber size and stroke
volume can be revered by COX-2 inhibition in rats with already established LV remodeling.
Similar results were observed with prevention treatment with HQL-79 a specific H-Prostaglandin
D synthase inhibitor, indicating that the PGD2 is a major driver for LV remodeling downstream
ii

of COX-2. Intervention treatment with HQL-79 showed, selective blockade of H- PGD synthase
can significantly reverse maladaptive changes in cardiac structure and function indicated by LV
mass index, chamber size, stroke volume and total collagen levels. In vitro studies on human
cardiac fibroblasts have shown that both prostaglandin D receptors the DP2 and DP2 receptors
down-regulate COX-2 expression. DP1 receptor was shown to up-regulate both Collagen 1A and
3A mRNA expressions, whereas DP2 receptor activation led to elevation of Collagen 1A and
reduction in collagen 3A mRNA expression. These results indicate that COX-2 and downstream
PGD2 are major drivers for pressure overload induced cardiac remodeling. H-PGD synthase was
found to be a potential therapeutic target to prevent and reverse left ventricular remodeling
induced by pressure overload.
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INTRODUCTION

Hypertension and heart failure:
Hypertension is a chronic disorder characterized by sustained elevation in blood pressure.
Blood pressure can be defined as the pressure exerted on the walls of the arteries which varies
from the maximum (when the heart starts contracting or cardiac systole) and the minimum (when
the heart is relaxing or cardiac diastole). Pressure changes of 120/80 mm/Hg (systole / diastolic)
are considered the normal arterial blood pressure for humans. Based on the severity,
hypertension can be classified into various stages. 1) Pre Hypertension (120-139/80-89) 2) Stage
1-hypertension (140-159/90-99) and 3) Stage 2-hypertension (>160/>100). Hypertension is
commonly categorized into two groups, primary hypertension (idiopathic hypertension) and
secondary hypertension. Primary hypertension is elevated blood pressure without a known
etiology. Secondary hypertension is elevated blood pressure due to one or more underlying
causative disorders like reno-vascular disorders, hormonal imbalance or pregnancy to name a
few.
According to the CDC, one in three adults in the United State is believed to be
hypertensive[1]. In 2008 about 61,000 deaths were directly related to hypertension in U.S. The
estimated direct and indirect cost of hypertension was nearly 50 billion dollars in 2008[2].
Hypertension is best known to be the major predisposing factor for congestive heart failure,
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atherosclerosis and myocardial infarction[3]. Studies have shown that in the blood pressure range
of 115/75 to 185/115, every 20/10 mm Hg increase doubles the chances of myocardial infarction
and stroke[4]. In people less than 45 yrs of age, hypertension is shown to be more prevalent in
males as compared to females, and African Americans were found to be more susceptible to
hypertension, as compared to white males in United States[5, 6]. According to the data collected
by the national health and nutrition examination survey between 2005 and 2008, nearly 80 % of
people with hypertension are unaware that they are hypertensive and roughly 50% of them do
not have it controlled.
The contribution of hypertension to heart failure is greater than any other known risk
factor[7]. The transition from a hypertensive heart to heart failure is comprised of multiple
stages. In people with chronic hypertension, Left ventricular remodeling occurs as a
compensatory change to hemodynamic stress[8]. The initial cardiac remodeling is associated
with improved contractility of cardiac muscle and maintenance of cardiac output to compensate
for the elevated ventricular pressure and afterload. However, prolonged stimulus from the
elevated blood pressure ultimately leads to a decompensated state of dilated cardiaomyopathy,
eventually leading to heart failure[7].

Left ventricular remodeling:
Left ventricular remodeling is characterized by alterations in shape, dimensions, mass
and compliance of the left ventricle due to physiological (i.e. exercise or pregnancy) or
pathophysiological stress (i.e. hypertension). Physiological cardiac remodeling is associated with
elevated cardiac performance, where as pathological remodeling is associated with maladaptive
changes including myocyte hypertrophy and extracellular matrix (ECM) remodeling, leading to a
2

loss in chamber size and compliance. Collagen, the major component of the ECM, is a fibrillar
protein which forms the scaffolding that provides structural support to myocardial muscle fibers
and vasculature[9]. Collagen is synthesized by the resident fibroblasts and is deposited in to the
extracellular space. Although nearly twenty different collagen phenotypes have been identified,
cardiac ECM is mainly composed of collagen type I and III. The total collagen, and more
importantly the ratio of collagen type I to type III determine myocardial tissue properties like
wall stiffness and compliance[10]. Collagen type I has a higher tensile strength as compared to
collagen type III. The ratio of collagen type I to collagen type III in the normal left ventricle is
known to be 1.93

. Studies have shown that during ischemic cardiomyopathy in humans,

total collagen levels are significantly increased as compared to controls (7.96 +/- 1.24 mg/g to
13.9 +/- 1.30 mg/g) and there is also a significant reduction in the ratio of collagen type I to type
III (1.93 +/- 0.52 to 1.23 +/- 0.27) [11]. Collagen type I levels remained the same, where as
collagen III levels significantly increased (2.56 +/- 0.21 mg/g to 6.10 +/- 0.58 mg/g ) in the
dilated hearts as compared to normal hearts. In contrast, hypertension induced left ventricular
remodeling is known to lead to a significant increase in collagen the I to III ratio increasing
tissue stiffness and reducing compliance, therefore effecting cardiac function[11].
Another important characteristic of cardiac remodeling is cardiac myocyte cell
hypertrophy. Cardiac myocytes are multinucleated striated muscle cells made up of numerous
bundles of myofibrils, which are comprised of repeating units of sarcomeres. Sarcomeres are the
functional units of the myocytes made up of actin and myosin filaments, which interact with each
other leading to contraction and relaxation [12]. Compensational hypertrophy of the myocytes
occurs as a result of hemodynamic stress[7]. Cardiac myocyte hypertrophy can be divided into
two group’s concentric and eccentric hypertrophy based on the method of the addition of
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sarcomeres. Concentric hypertrophy occurs due to the addition of new sarcomeres in parallel to
old ones, leading to increased wall thickness. Concentric hypertrophy usually occurs during
pressure overload. In eccentric hypertrophy the newer sarcomeres units are added in series to
older units, leading to elongation of myocytes. This type of hypertrophy leads to an increase in
chamber dimension without effecting wall thickness. Eccentric hypertrophy usually occurs in
response to volume overload to accommodate for increased stroke volumes[9, 12].

The role of TNF-  cardiac remodeling:
The exact mechanistic pathway(s) responsible for LV remodeling during stress are
unknown[13]. Various studies point towards inflammation as the major driver for stress induced
cardiac remodeling.
Hemodynamic stress is known to stimulate resident cardiac and infiltrating immune cells
to synthesize and secrete several autocrine and paracrine signaling molecules knows as cytokines
and interleukins. One of the most commonly studied cytokines associated with cardiac
remodeling is tumor necrosis factor alpha (TNF-). Several studies have shown elevated levels
of TNF-in people with heart failure [14, 15], although the exact mechanism behind the
stimulation of TNF-upregulation is not clearly understood. TNF- is involved in inflammation
with a myriad of direct effects on cardiac tissue such as LV remodeling, LV dysfunction and
cardiomyopathy depending on the receptor and the cells stimulated [14, 15]. Mei Sun et al,
showed significant elevation of TNF-levels in the heart post descending aortic banding and
TNF- with aortic banding had shown attenuation of LV dysfunction as compared to SHAM
operated wild type mice. These mice also demonstrated reduced matrixmetalloproteinase-9
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activity and improved cardiac function. TNF- is known to activate different cell signaling
cascades leading to various effects which can sometimes be contradictory to each other.
Condorelli G et al demonstrated the role of AKT / NF-kB and JUN Kinase in TNF- mediated
neonatal cardiac myocyte hypertrophy. The same group also found that inhibition of AKT / NFkB and JUN Kinase pathways did not prevent myocyte hypertrophy indicating complex etiology.
Although up regulated levels of TNF- is used for heart failure prognosis, there is no evidence of
beneficial effects of TNF- inhibition on cardiac hypertrophy[14].

The role of TGF- on cardiac remodeling:
Another well studied inflammatory mediator associated with LV remodeling is
transforming growth factor- (TGF-), which has been associated with cardiac hypertrophy and
excessive collagen production or fibrosis. A study by Lim JY et al showed that neonatal cardiac
myocytes treated with TGF- lead to a hypertrophic response via TAK1-MKK3/6-p38 MAPK
signaling pathways[16]. TGF-receptor antagonism has been shown to attenuate myocardial
fibrosis in mice with cardiomyopathy[17]. Kuwahara F. et al has shown anti-fibrotic effects of
TGF- inhibition using anti TGF- antibodies administered IP daily, on pressure overloadinduced cardiac hypertrophy [18]. Although anti TGF- antibodies showed anti-fibrotic effects,
they had no effect of myocyte cell hypertrophy. Lucas JA et al demonstrated cardio-myopathic
effects of TGF- inhibition in pressure overloaded due to significant reduction in collagen
deposition[19]. Overall, TGF- inhibition attenuates ventricular fibrosis induced by pressure
overload, but causes possible deleterious ventricular dilation in pressure overloaded hearts [20,
21].
5

Interleukins and cardiac remodeling:
Interleukins are pleiotrophic cytokines with a myriad of functions. Earlier studies have
demonstrated elevated circulating levels of interleukins-1 in essential hypertension[22]. Other
studies have shown elevated levels of interleukin-6 in patients with heart failure[14]. Interleukin6 treatment infusion was shown to cause fibrosis and concentric hypertrophy in Sprague Dawley
rats, independent of change in blood pressure. Cardiac fibroblasts treated with IL-6 were shown
to elevate collagen production and phenotypic transformation of fibroblasts to myofibroblasts.
Although these cytokines have been previously investigated, there remains a distinct lack benefit
from their inhibition. Besides cytokines (i.e. TNF-, TGF-) and interleukins, the major
inflammatory modulators are prostaglandins.

Prostaglandins and cardiac remodeling:
Prostaglandins are fatty acid derivatives composed of 20 carbons with a 5 carbon ring.
Prostaglandins have a very short half life (seconds to a few minutes) and act via autocrine or
paracrine signaling. Although prostaglandins are synthesized and secreted in very small
concentrations (pico-nano molar concentrations), they have significant biological impacts such
as inflammatory mediation and hormonal regulation. Prostaglandins have a myriad of effects
depending on the type of receptors expressed in the tissue(s) and the prostaglandins involved.
Prostaglandins are known to cause vasodilatation or vasoconstriction depending on the tissue and
prostaglandins involved Platelet aggregation, control cell growth and thermoregulation. One of
the most prominent effects of prostaglandins is the initiation of the inflammatory response to
stress or toxic stimulus leading to pain and fever. Prostaglandins are also associated with certain
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cardiovascular effects like cardiomyocyte cell hypertrophy and fibrosis depending on the specific
prostaglandin. The biochemical precursor for all prostaglandins is arachidonic acid. Arachidonic
acid is cleaved from the phospholipids in the cell membranes by the action of enzyme
phospholipase A2. Cyclooxygenase enzymes catalyze the conversion of arachidonic acid into
prostaglandin H2, which is a precursor for all other prostaglandins such as prostaglandin E2,
prostaglandin F2, prostaglandin I2 and thromboxanes. Prostaglandin H2 is converted
enzymatically into all other prostaglandins by the actions of specific individual synthases which
are expressed in a tissue specific manner.
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Role of COX-2 and remodeling:
The main regulators of prostaglandin synthesis are the cyclooxygenase group of enzymes.
Three different types of cyclooxgenases have been identified to date, COX-1 COX-2 and COX3. COX-3 was later found to be a splice variant of COX-1. Until recently COX-2 is thought to be
an inducible enzyme, as opposed to the constitutively expressed COX-1. However, research in
the last decade showed the constitutive expression of COX-2 in various tissues. Numerous
studies were done to evaluate the role of COX activity and inhibition on cardiac remodeling in
models of infarction and heart failure.
LaPointe MC et al. showed that COX-2 inhibition significantly attenuated the cardiac
hypertrophy and collagen deposition post myocardial infarction induced by ligation of the left
anterior descending coronary artery in mice[23]. Parecoxib, a selective COX-2 inhibitor was also
found to be beneficial in improving cardiac function in the rat model of ischemic heart failure by
significantly attenuating cardiac myocyte apoptosis and preserving vascularity. Delgado et al.
showed a significant improvement in overall mortality and left ventricular remodeling with
COX-2 inhibition in a doxorubicin model of heart failure in rats[24]. While COX-2 inhibition
was found to be beneficial in improving cardiac function, the mechanistic pathway(s) involved
are not known. In particular, there are no studies describing the role of specific COX-2 inhibitors
on pressure overload induced cardiac remodeling. The chronic COX-2 inhibition was also
associated with various adverse effects including renal hemodynamic complications due to an
altered balance between Prostaglandin I2 and the thromboxanes[25]. Rofecoxib, a selective
COX-2 inhibitor has been withdrawn from clinical use after VIGOR (Vioxx GI Outcomes
Research) study indicated a significant increase in cardiovascular and renal complications after
chronic selective COX-2 inhibition. One of the known causes for hemodynamic complications
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associated with COX-2 inhibition is the reduction in vascular prostacyclin levels leading to
imbalance between anti-thrombotic PGI2 and pro-thrombotic thromboxane A2, leading to
cardiovascular thrombotic events[26].
Because COX-2 inhibition leads to global down regulation of all prostaglandins leading
to cardiovascular adverse effects, identifying a specific prostaglandin involved in cardiac
remodeling would help identify a novel therapeutic target for drug development aimed at
preventing cardiac remodeling without precipitation of significant adverse cardiac events.
Although the cardiovascular effects of individual prostaglandins in other cardiovascular
disorders are recently coming to light, the specific cardioprotective or adverse roles of
prostaglandins and their mechanistic mode of action in attenuating pressure overload (PO)
induced cardiac remodeling is still relatively unknown.

Prostaglandin E2 in remodeling:
PGE2 is biosynthesized by action of Prostaglandin E synthases (PGE synthases) on
prostaglandin H2. PGE2 is known to act via the binding to one of its four G protein coupled
receptors (EP1– 4) resulting in various biological effects such as vasodilation, smooth muscle
relaxation, thermoregulatory effects on CNS, sodium excretion and hemodynamic regulation.
Compared to all other prostaglandins, Prostaglandin E2 is most widely studied for its role in the
cardiovascular system. The Gi coupled EP3 receptor was demonstrated to have anti fibrotic
effects, but was also associated with pro-hypertrophic activity. Studies conducted on neonatal
cardiac myocytes by Mendez et al. has shown that the antihypertrophic actions of COX-2
inhibitors are mediated through inhibition of PGE2 formation[27]. Mendez et al later
demonstrated that the PGE2 receptor induced hypertrophic effects were mediated by an EP4
9

receptor subtype via the p42/44 MAPK pathway[28]. Recently, cardioprotective and
antihypertrophic effects of PGE2 were reported after reperfusion injury[29]. Moreover, 14 week
old cardiac specific EP4 receptor knockout mice showed impaired cardiac function and was also
associated with attenuated cardiac remodeling post myocardial infarction[30]. Although EP4
knockout mice were found to be cardioprotective post myocardial infarction, a longitudinal study
done on 23-33 week old male and female rats by Harding et al. showed that cardiac specific EP4
knockout rats developed decreased cardiac function and developed cardiomyopathy[31].

Prostaglandin F2 in remodeling:
Prostaglandin F2 is known to act via its G protein coupled (Gq) FP receptor expressed in
the cardio-vasculature leading to increased intracellular calcium levels. mRNA expression
studies on left ventricular tissues have shown that the expression of FP receptors was the highest
compared to all other prostaglandin receptors[32]. Prostaglandin F2 was found to induce
hypertrophy in neonatal cardiac myocytes through its receptor (FP)[33]. This was further
confirmed by Lai et al in adult cardiac myocytes[34].In vivo administration of Fluprostenol, a
stable analog of PGF2 which a potent FP receptor agonist was found to cause cardiac
hypertrophy which is evident from elevated LV mass index. The pro-hypertrophic actions of FP
receptor activation were linked to the MEK-ERK2 signaling cascade[35]. Recent studies
investigated stable certain stable metabolites of PGF2 such as 8-epi-prostaglandin F2α as
important biomarkers for severity of heart failure and cardiac function in humans (). The role of
PGF2 and its receptors in cardiac remodeling secondary to pressure overload is currently
unknown; although FP receptor might have an active role in mediating stress induced cardiac
remodeling, elucidating it is not in the scope of this study.
10

Prostaglandin I2 in remodeling:
Prostaglandin I2 (PGI2) which is also known as prostacyclin is biosynthesized by the
action of both COX-1 and COX-2. The G protein coupled prostacyclin receptor; IP is known to
be widely expressed in the cardio-vasculature and acts via the Gs subunit to elevate intracellular
cAMP levels. Activation of its receptor (IP) has shown to have antihypertrophic effects. IP -/knockout animals have shown to have significantly elevated PGI2 was shown to have
cardioprotective effects in ischemia/ reperfusion model in mice [36] . As compared to the sham
operated controls, IP-/- knockout mice also demonstrated elevated cardiac myocyte hypertrophy
in mice with pressure overload induced by abdominal aortic constriction [37]. In contrast, IP
receptor activation by the PGI analog Cicaprost, failed to cause cardiac hypertrophy suggesting
the role of atrial natriuretic peptide in PGI mediated cardiac hypertrophy. A study done by
Francois et al demonstrated that IP-/- in SHR rats led to significant cardiac hypertrophy as
compared to wild type controls (). It is important to note that the potential therapeutic use of
PGI2 agonists could be limited due to vascular side effects seen from imbalances between PGI2
and thromboxane A2 (TXA2) as seen in the case for selective COX-2 inhibitors such as VioxxTM,
which inhibit downstream PGI2 along with other prostaglandins without affecting TXA2[38].

Prostaglandin D2 in remodeling:
Prostaglandin D2 (PGD2) biosynthesis is regulated by two specific synthases;
hematopoietic prostaglandin D synthase (H-PGD synthase) and lipocaline prostaglandin D
synthase (L- PGD synthase) on Prostaglandin H2. PGD2 has two G protein coupled receptors,
DP1 and DP2 both of which are present in the heart. DP1 receptor is linked to Gs  (increasing
cAMP) and is known to inhibit cytokine release and chemotaxis. The DP2 receptor is known to
11

act via Gi (decreasing cAMP) and promote cytokine release and chemotaxis[39]. The role of
PGD2 and its receptors in cardiovascular system during pathological stress is still unclear.
According to Gupte et al. in a stressed myocardium the levels of prostaglandin D2 undergo the
greatest elevation compared to all other prostaglandins[40]. Schuligoi et al has shown that HPGD synthase mRNA expression was significantly increased in the heart post lipopolysaccharide
(LPS) treated inflammation model in mice [41]. Similar results were found in our lab which
showed an increase in H-PGD synthase protein levels after 14 day post pressure overload in
rats[42]. These findings point towards a specific inflammatory pathway involving PGD2 and its
specific receptors in mediating stress induced cardiac remodeling. Therefore, the goal of this
study is to establish the potential cardioprotective effects of H-PGD synthase inhibition and the
pathway(s) involved.
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MATERIALS AND METHODS:

Drugs used:
Nimesulide: Nimesulide (Tocris BioscienceTM (Bristol, UK)) is a selective COX-2 inhibitor with
IC50 of 70M for COX-1 and 1.27M for COX-2 (at 20mg arachidonic acid substrate[43].
Nimesulide (Nime) was used at a dose of 25 mg/kg/day in 10% ethanol administered
subcutaneously.

HQL 79: HQL 79 (Caymen Chemicals, Ann Arbor, MI) is a selective hematopoietic Prostaglandin D synthase (H-PGD synthase) inhibitor with an IC50 of 6 M. HQL 79 was orally
administered with 0.5% methylcellulose in saline at a dose of 1 mg/kg/day.

BW245C: BW245C (Caymen Chemicals, Ann Arbor, MI) is a selective DP1 receptor agonist.
BW245C was used at a concentration of 0.1mM in 10 % ethanol.

BWA868C: BWC245C (Caymen Chemicals, Ann Arbor, MI) is a selective DP2 receptor
antagonist with a Ki of approximately 1.7nM. BWA245C was used at a concentration of 0.1 mM
in 10 % ethanol.
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13, 14- di hydro- 15-keto PGD2: 13, 14 dihydro-15-keto PGD2 (Caymen Chemicals, Ann
Arbor, MI) is a metabolite of prostaglandin D2 and specifically agonizes the DP2 receptor. 13-14di hydro- 15-keto PGD2 was used at a concentration of 100M in 10% ethanol.

BAY u3405: BAY u3405 (Caymen Chemicals, Ann Arbor, MI) is a specific DP2 receptor
antagonist with an IC50 of 100-170 nM. It has also been documented to have mild thromboxane
receptor antagonist properties. BAYU3405 was used at a concentration of 100mM in 10%
ethanol.

GW9662: GW9662 (Caymen Chemicals, Ann Arbor, MI) is potent PPAR gamma receptor
antagonist with an IC 50 of 3.3nM. This compound acts as antagonist for PPAR alpha and PPAR
delta with IC 50 of 32nM and 2000nM respectively. GW9662 was used at a concentration of
100M in 10 % ethanol.

U0126: U0126 (Caymen Chemicals TM (Ann Arbor, MI)) is a selective MEK ½ inhibitor with
IC50 values of 72 nM and 58 nM respectively. U0126 was used at a concentration of 100mM in
10 % ethanol.

PGD2: prostaglandin D2 was obtained from Caymen Chemicals TM (Ann Arbor, MI).

PGJ2: Prostaglandin J2 was obtained from Caymen Chemicals, Ann Arbor, MI).
All other chemical reagents were obtained from fisher scientific (st louis, MO) unless otherwise
specified.
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Methods:
Animals used:
Adolescent male Sprague Dawley rats were used for the studies. Rats were housed in a standard
colony room with controlled temperature (22 ), and 12h light/12h dark cycles. Food and water
were provided ad libitum. All procedures involving animals were approved by the Institutional
Animal Care Use Committee of the University of Mississippi according to the National Institutes
of Health Guide for Care and Use of Laboratory Animals.

Surgical induction of pressure overload:
Pressure overload was induced by means of aseptic survival surgically induced
abdominal aortic constriction. Anesthesia was induced and maintained using isoflurane gas
anesthetic at a flow rate of 2.5l/min. Animals were placed on a heated pad at 37°c during the
procedure to help maintain core body temperature. Under aseptic conditions, a one inch incision
was made on the linea alba (to minimize blood loss) slightly below the xiphoid process. The
animals were then disemboweled and the abdominal aorta was identified. A zero silk ligature
was passed under the abdominal aorta in between the left and right renal artery. A blunt 22 gauge
needle was then carefully placed on the abdominal aorta and tightly constricted using the silk
ligature. The needle was quickly removed leading to the coarctation of the abdominal aorta to the
external diameter of the 22 gauge needle. Post constriction, bowels were moved back into the
abdominal cavity and the musculature was closed using an absorbable suture (Chromic 3-0). The
skin incision was closed with skin staples. The rats were left to recover in a heated recovery unit.
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Assessment of cardiac function:
In vivo left ventricular chamber volume and functions was assessed using the Scisense
ADVantageTM (Ontario, Canada) pressure volume admittance catheter. Anesthesia was induced
in the animals using isoflurane gas anesthetic in an induction chamber and was maintained with
Sodium Pentobarbital IP. A small mid line neck incision was made and blunt dissection was
done to identify the carotid artery. After the distal blood flow in the isolated region of the carotid
was controlled by ligation and the proximal end was suspended with a silk ligature at tension to
prevent blood flow. A small incision was made and the pressure/volume (P/V) catheter was
carefully placed in the carotid artery. A zero silk ligature was tied around the blood vessel
around the catheter to prevent blood loss. The catheter was then advanced into the left ventricle
via the carotid artery. Data was analyzed using iWorx© (Dover, NH) Labscribe Instrument
software. Mean Arterial Pressure was calculated as Diastolic pressure + 1/3(Systolic pressure –
Diastolic Pressure. Max dP/dt, the peak rate of maximal pressure rise, was reported as an
indicator of contractility. The slope of the End Diastolic Pressure Volume Relationship
(EDPVR) was reported as an indicator of passive tissue property (e.g. ventricular compliance,
thus, the steeper the curve, the greater the ventricular stiffness). Min dP/dt, peak rate of pressure
decline over time, and Tau, the isovolumic relaxation constant, provided indices of ventricular
relaxation.

Tissue collection:
After the animals by were euthanized by surgical isolation of the hearts under deep
anesthesia; the heart, kidneys and blood were collected; left and right ventricles were identified
and isolated. The mass of the ventricles and each kidney were weighed. The apical regions of the
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heart were collected and snap frozen in nitrogen for protein analysis. The septal wall of mid
section of the heart was isolated and used for HPLC analysis of Prostaglandin D2, prostaglandin
J2 and prostaglandin F2 alpha. The tissue from the non-septal mid section was used to measure
the total collagen using hydroxyproline analysis.

Protein Extraction:
The apical regions of the left ventricles were used for protein analysis. 100mg of LV
tissue was measured and placed in 800l of homogenizing buffer (1X protease inhibitor cocktail,
PBS). The tissues were homogenized using a hand held tissue homogenizer. 80 L of cell lysis
buffer (10% PBS-Tween) was added and the homogenate was centrifuged for 30 mins at
16000rpm. The supernatant was collected and used for protein analysis.

Protein Quantification:
Total protein quantification was done using DCTM protein assay (Bio-Rad, Hercules CA).
Bovine serum albumin in PBS protein standards concentrations ranging between 0.1g/l and
4g/l were prepared 0.5 l of protein extracts and standards (in triplicates) were loaded in a 96
well plate. 200ml of reagent A and 25 ml of reagent B provided by the manufacturer were added
to each well. As per the instructions absorbance corresponding to protein concentration was
measured at 750nm.

17

Hydroxyproline analysis for total collagen:
The mid section (non-septal region) of the left ventricular tissue (50 mg) was dried in an
80 °C oven and then hydrolyzed in 6 N HCl at 110 oC for 18 hr. After hydrolysis, samples were
decolorized using 2mg of activated charcoal. The charcoal was then filtered, and the filtrate dried
using vacuum rotary evaporator. The samples were re-suspended in specified citrate buffer and
the hydroxyproline concentration was determined using the method described by Woessner[44].

Western blotting:
Gel electrophoresis (12% SDS-PAGE) is carried out with the left ventricular (LV) tissue
and cell extracts at 200 V for 45 mins. The proteins were then transferred onto a nitrocellulose
membrane using a semi-dry transfer apparatus. The blots were probed with rabbit polyclonal
antibodies specific to COX-2, H-PGD synthase, DP1 or DP2 and an internal normalization
control (GAPDH). Anti-rabbit goat secondary antibody tagged with horseradish peroxidase was
added to the primary antibodies and blots were visualized using ECL chemiluminiscent reagent
on the VersadocTM imaging apparatus (Bio-radTM).

ELISA (enzyme linked immune sorbent assay):
Commercially available ELISA kits were used to assess the protein concentrations of
TNF- and TGF-  (R and D systems, Minniapolis, MA). TNF  ELISA was carried out by
loading 50 l of rat tissue followed by dilution with 50 l of calibrator diluents provided in the
kit into each well of the ELISA plate (pre coated with monoclonal TNF-) and incubated for 2
hrs. Rat TNF- conjugate solution was added as recommended. After the addition of the
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substrate solution the absorption was measured at 450nm with a correction at 570 nm. Results
were reported as ng/ml, a similar procedure was employed using corresponding TGFmonoclonal antibodies to detect the levels of TGF-levels in the LV extracts.

Cell culture:
Primary human cardiac fibroblasts cells (HCF) were obtained from Sciencell (Carlsbad,
CA). The cells were grown in DMEM supplemented with 10% Fetal bovine serum (Cellgro,
Manassas, VA), and 5 % Neonatal calf serum (Sciencell), Fibroblast growth serum (Sciencell),
5g / ml Plasmocin Prophylactic (Invivogen, San Diego, California) and 1X Antibiotic –
Antimycotic solution (Cellgro, Manassas, VA). HCFs were grown in 100 mm cell culture dishes
containing fibroblast growth media. When the cells reached 80% confluence, they were serum
starved for 24 hrs in 2% fetal bovine serum. Depending on the assay and drug treatment, the cells
were treated for 45 mins or 48 hrs in growth media. At the end of treatment, the cells were
scraped in 1x cell Lysis buffer (cell signalingTM, Danvers, MA), supplemented with protease
inhibitor cocktail. Cells solutions were sonicated and centrifuged. The extracts were for further
protein analysis as described above.

COX-2 cell based ELISA (Human / Mouse Total COX-2 Immunoassay):
10000-20000 cells per well in 200l of media were plated in each well of a 96 well plate
and were allowed to attach incubated overnight at 37 °C. The media was replaced with serum
starve media after the cells reached 90% confluence. The cells were then treated with the various
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compounds of interest in a total volume of 200l. The cells were fixed with 4% formaldehyde
for 30 mins. After fixation, blocking reagent (Bovine serum albumin) was added to all wells and
incubated for 2 hrs; the blocking reagent was then replaced with 100l of provided antibodies
specific to COX-2 and GAPDH were added to the wells. After addition of specific signaling
reagents provided by the manufacturer, fluorescence was measured as per manufacturer
recommendations (R&D systems).

Collagen gene expression analysis:
HCF cells were seeded in 12 well plates at 4x106 cells per well in 3ml media and treated
with the various compounds at specified doses for 48 hrs. Cells were lifted using 0.5ml of trypsin
and centrifuged to form a pellet and were, washed with PBS, and RNA was isolated with the
RNeasy Mini kit (Qiagen, Valencia, CA). Up to 500 ng of cDNA were reverse transcribed with
the qScript cDNA SuperMix (Quants Bio Sciences) prior to quantitative real-time PCR detection
on the Bio-Rad CFX connect thermocycler with FAM-labeled TaqMan primers were obtained
from Applied Biosystems (Carlsbad, CA) for Collagen I and III. VIC-labeled GAPDH TaqMan
primers were also obtained from Applied Biosystems (Carlsbad, CA); the ΔΔCt method was
used to calculate changes in expression, normalized to the appropriate time-matched vehicletreated control cells.
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AIM: 1
Efficacy of acute selective COX-2 inhibition using Nimesulide on
attenuating pressure overload induced cardiac remodeling.
Introduction:
It is established that pressure overload is associated with structural and functional
maladaptative remodeling of the left ventricle [12]. Although the specific molecular pathway
leading to maladaptive remodeling is unknown, previous studies suggest inflammation is a key
component in stress induced maladaptive cardiac remodeling[13]. Specific inhibition of COX-2,
which is responsible for the enzymatic conversion of arachidonic acid to PGH2 a precursor for
the synthesis of all prostaglandins has been demonstrated to attenuate maladaptive cardiac
remodeling in animal models of heart failure and myocardial infarction[23, 24]. Although several
studies point towards beneficial effects of COX-2 inhibition, clinically chronic COX-2 inhibition
is limited due to adverse effects linked to their use. Reviews by Moodley and Mukherjee have
documented that the renal and vascular adverse effects of chronic COX-2 inhibition are due to
altered balance of certain prostacylins and thromboxanes on prolonged use of COX-2
inhibitors[25]. These cardio-renal adverse effects were linked with chronic clinical usage of
COX-2 inhibitors. If acute treatment with COX-2 inhibitors is found to be beneficial, we
therefore hypothesize that they can be clinically used to attenuate cardiac remodeling in the early
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stages of hypertension without precipitating adverse effects associated with chronic COX-2
inhibition.

Rationale:
The effect of acute COX-2 inhibition on attenuating the structural and functional changes
associated with pressure overload induced myocardial stress is currently unknown. We designed
this study to evaluate changes in the chamber dimension and function, along with other
biochemical parameters such as COX-2 expression, Collagen expression and PGD synthase
expression in the LV secondary to pressure overload from acute COX-2 inhibition. Based on the
studies that support a cardioprotective role for selective COX-2 inhibitors in other models of
heart failure [13,14,15], we hypothesized that such COX-2 inhibition would attenuate the
remodeling induced by pressure overload. Identifying a short term treatment strategy during the
initial stages of remodeling could potentially prevent the early maladaptive cardiac remodeling
that is responsible for the loss of cardiac function, without precipitating chronic treatment
induced adverse effects and represent a significant change in the current treatment paradigm.

Objective:
Study the effects the selective COX-2 inhibition using Nimesulide in attenuating cardiac
remodeling on pressure overloaded rats at the 14 day time period.

Approach:
Nine week old Sprague Dawley rats were housed under standard environmental
conditions (12 hr light/12 hr dark) and fed commercially available chow and tap water ad
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libitum. Surgical induction of pressure overload was achieved by performing a coarctation of the
abdominal aorta between the left and right renal arteries. Treatment groups included 1) shamoperated surgical control group (SHAM); 2) untreated pressure overloaded (PO) group and 3)
Nimesulide treated (NIME) pressure overload group (25mg/kg/day s.q.). Treatment was initiated
one day prior to induction of pressure overload and was continued till day 14 post surgery.
NIME treated – sham operated controls and vehicle treated (10% ethanol) controls were also
included. Cardiac structural (chamber size, LV mass) and functional (stroke volume, Max dP/dt,
Tau coefficient, end diastolic pressure volume relationship (EDPVR)) parameters were assessed
on day 14 using a Scisense (Scisense Inc, Ontario, Canada) admittance catheter. Myocardial
COX-2 and H-PGD synthase levels were assessed by western blotting. Myocardial L-PGDs
levels were assessed using ELISA. Myocardial total collagen levels were assessed by
hydroxyproline assay for total collagen. One way ANOVAs were performed using GraphPad
Prism software (GraphPad Software, San Diago, CA). All grouped data are expressed as means
of +/- SEM, unless otherwise mentioned. Grouped data comparisons were performed using one
way ANOVA with bonferroni post hoc test. Statistical significance was taken to be p<0.05.

Results:
Relative to age-matched SHAM, 14 day untreated PO and 14 day NIME treated animals
had significant reduction in body mass (Table 1). The significant reduction is body weight post
surgery is consistent with surgical stress. 14 days post induction of pressure overload, LV mass
of PO animals was found to be significantly elevated, as compared to the sham controls.
Nimesulide treatment significantly attenuated this pressure overload-induced increase in LV
mass. The increase in LV mass is still significant vs SHAM animals when the mass is
23

normalized to body weight. Nimesulide treatment significantly attenuated this change. Right
ventricular mass did not show any significant difference in PO rats as compared to SHAM
controls. The right kidney mass was not significantly affected by pressure overload surgery
whereas the left kidneys showed a significant reduction in mass post-pressure overload, as
compared to the SHAM control. Significant reduction in left kidney mass is most likely due to
reduced blood flow to the left kidney due to the arterial coarctation (Table 1).

Table 1: Comparison of body weights, LV, RV and kidney wet weights in 14 – day post
surgery.
Parameters:
in vivo conductance
catheter

Sham-Operated

14-day untreated PO

14- day NIME treated

Body weight (g)

335 ± 5

284±8*

296 ± 9*

LV mass (mg)

752 ± 5

839 ± 27*

739 ± 19¥

LV/Body weight
Ratio

2.2 ± 0.01

2.9 ± 0.1*

2.5 ± 0.03*

RV mass(mg)

181 ± 6

170 ± 6

155 ± 5*

Rt Kidney mass (mg)

1107 ± 28

1222 ± 117

1131 ± 73

Lt Kidney mass (mg)

1099 ± 22

658 ± 43*

755 ± 67*¥

Table 1: Comparison of body weights, LV, RV and kidney wet weights in 14 – day post surgery

sham-operated, PO and PO + NIME groups.*Denotes P ≤ 0.05 compared with sham.¥ Denotes P
≤ 0.05 compared with untreated PO. Values are reported as mean ± SEM (n≤7).

Heart rate was unchanged in PO rats, but significantly elevated in the NIME animals as
compared to sham-operated animals. Mean arterial pressure was significantly increased in both
PO groups, as compared to SHAM but it is attenuated by NIME intervention, this which was
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consistent with the elevated LV end systolic pressures in the PO groups (Table 2). Left
ventricular end diastolic pressure was not different between any of the groups. Multiple indices
of systolic performance (i.e. max dP/dt, stroke work, and preload recuitable stroke work (PSRW)
were significantly increased in the untreated PO group relative to SHAM control. Of these
functional parameters, Stroke work was increased by 53% in the untreated PO group compared
to Sham values. Treatment with Nimesulide significantly attenuated stroke work compared to the
untreated PO group.
Left ventricular end systolic and diastolic volumes were significantly reduced in the
untreated PO group relative to SHAM (Table 2). Treatment with NIME prevented the POinduced changes in these parameters and fully attenuated them to SHAM levels. Tau, an
indicator of LV relaxation rate, was markedly increased in the PO hearts but preventative
treatment with NIME significantly attenuated the PO induced change. Ventricular stiffness as
measured by the slope of the end diastolic pressure volume relationship (EDPVR) trended to be
significantly higher in the PO group as compared to the SHAM animals; this change was
significantly attenuated by NIME treatment.
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Table 2: Structural and functional parameters of 14 day controls, PO and NIME treated
animals.

Parameters:

Sham – operated

14-day untreated
PO

14-day Nimesulide –
treated PO

Heart rate (bpm)

324 ± 8

342 ± 15

363 ± 9*

End systolic pressure (mmHg)

121 ± 3

177 ± 9*

170 ± 8*

End diastolic pressure
(mmHg)

4 ± 0.3

3 ± 0.5

4 ± 0.6

Mean arterial pressure
(mmHg)

115 ± 7

155 ± 4 *

141 ± 5 *¥

End systolic volume (l)

193 ± 17

127 ± 15 *

226 ± 9¥

End diastolic volume (l)

331 ± 14

281 ± 16*

324 ± 15 ¥

Stroke work (mmHg x mL)

14,303 ± 1430

21900 ± 2203*

13906 ± 1232¥

PRSW (mmHg)

58 ± 9

83 ± 9 *

93 ± 10*

Max dp/dt (mmHg/s)

7367 ± 182

10801 ± 457 *

10064 ± 494*

Min dp/dt (mHg/s)

-7096 ± 440

-9044 ± 745*

-10195 ± 247*

EDPVR

0.027 ± 0.01

0.039 ± 0.01

0.028 ± 0.01¥

Tau (Galantz)

14 ± 0.3

18 ± 1.4*

13 ± 0.4¥

in vivo conductance catheter

Table 2: Systolic and diastolic parameters in 14 days post surgery sham-operated , PO and PO +
Nime groups via in vivo conductance catheter.*Denotes P ≤ 0.05 compared with sham.¥ Denotes
P ≤ 0.05 compared with untreated PO. Values are reported as mean ± SEM.
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Figure 1: Analysis of total myocardial COX-2 Protein expression in the14 day SHAM, PO
and NIME treated groups.

Myocardial COX-2 expression
(normalized to GAPDH)

0.5

0.4

**

0.3

0.2

0.1

0.0
SHAM

PO

NIME

Figure 1: Analysis of total myocardial COX-2 Protein expression SHAM, PO and NIME treated
groups (n≥7). Values are reported as mean ± SEM. (* denotes p<0.05 compared to SHAM,
**denotes p< 0.02 compared to SHAM).

Compared to SHAM controls, PO animals did not show significant alteration in
myocardial COX-2 protein expression levels. NIME treatment significantly reduced COX-2
protein expression as compared to both the SHAM and PO groups (Figure 1). Furthermore,
significant up regulation of myocardial H-PGD synthase was observed in PO vs Sham animals.
This increase was significantly attenuated in the NIME group (Figure 33).
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Figure 2: Analysis of total myocardial collagen expression in the14 day SHAM, PO and
NIME treated groups.

Figure 2: Analysis of total myocardial collagen expression in sham-operated (SHAM), Pressure
overloaded (PO) and Nimesulide treated groups (NIME). n≥6 per group. Values are reported as
mean ± SEM (* denotes p<0.05)

Compared to SHAM controls, PO animals showed significant increase in total collagen
levels, as indicated by the hydroxyproline assay for total collagen (figure 2). The collagen levels
in NIME group were not significantly different from either the PO group or the SHAM groups.
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Figure 3: Analysis of H-type PGD synthase expression in the14 day SHAM, PO and
NIME treated groups.

Figure 3: Analysis of total myocardial H-type PGD synthase expression in sham-operated
(SHAM), Pressure overloaded (PO) and Nimesulide treated groups (NIME). n≤6 per group.
Values are reported as mean ± SEM. (* denotes p<0.05)

Discussion:
Previous studies have linked inflammation as the key component of stress induced
cardiac remodeling [9]. COX-2, one of the prominent mediators of inflammation was found to be
significantly elevated in the models of ischemia / reperfusion models of myocardial stress. In the
setting of pressure overload, our results show no change in the myocardial levels of COX-2
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enzyme after 14 days of pressure overload although treatment with the COX-2 specific inhibitor
Nimesulide (NIME) significantly reduced myocardial COX-2 protein levels. This NIME effect is
consistent with other investigations that demonstrated a positive feedback via downstream
prostaglandins in favor of expression of COX-2, and not COX-1. Specifically PGE2 and 15-JPGD2 were shown to induce COX-2 mRNA expression. 15-J-PGD2 is a non-enzymatic
degradation product of PGD2. PGD2 is synthesized from PGH2 by the action of its specific
synthases Hematopoietic-prostaglandin D synthase (H-PGD synthase) and Lypocaline
Prostaglandin D synthase (L-PGD synthase). Our study showed a marked increase in Myocardial
H-PGD synthase and a marked decrease in L-PGD synthase in PO group at day 14 post induction
of pressure overload as compared to the SHAM controls. Previous studies found that changes in
prostaglandin levels are associated with estrogenic cardioprotection [45, 46]. Specifically, LPGD synthase expression is regulated by the β subclass of estrogen receptors (ER), which are
found in both myocytes and cardiac fibroblasts[47]. Strong evidence exists that removal of the
ovaries, and a subsequent loss of estrogen ER- dependent loss of cardioprotection against
adverse remodeling, and abolishes myocardial L-PGD expression as well. A similar phenomenon
was documented by Tokudome et al[48]. Where the authors investigated the beneficial effects of
dexamethasone (glucocorticoid receptor agonist) during cardiac ischemia/reperfusion injury. GR
activation reduces infarct size; however, this effect was greatly diminished in L-PGD deficient
mice. Combining these studies with our own findings suggests that a reduction in L-type PGD
may promote adverse cardiac remodeling.
It is documented that the potential for cross-over effects between individual prostaglandin
receptor systems and various prostaglandins exists[49]. Moreover, these mediators often work in
concerted pairs to bring about agonist and antagonist effector activities even within the
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cardiovascular system. Further, the response of individual gene expression to decreased feedback
from the ultimate product formation may in one instance promote further expression of the target
gene or bring about a reduction in gene expression depending upon the promoter system
associated with the target gene. H-PGD and L-PGD synthase are commonly expressed in
separate organ systems throughout the body, but are yet co-expressed in the heart. While
Nimesulide has been extensively characterized as a selective COX-2 inhibition [50, 51] there has
been no study to date of any interaction with a PGD synthase. It is plausible that Nimesulide is
mediating effects on specific PGD synthases as well as altering their expression patterns. The
current study did not explore these potential directs effects they remain as potential mechanism
to explain our findings.
Pressure overload is associated with resultant changes in hemodynamic and mechanical
load leading to increased myocardial stress. After two weeks, systolic function was enhanced in
the pressure overload group, as indicated by maximum dP/dt, preload recruitable stroke work,
and end systolic pressure. The use of the selective COX-2 inhibitor Nimesulide concordant with
PO induction did not affect arterial blood pressure or cardiac contractility. However, Nimesulide
did attenuate changes in LV mass and chamber morphology. Herein, we report PO-induced
changes in Tau, EDPVR, and collagen content indicative of adverse changes in passive tissue
properties, which were attenuated by COX-2 inhibition. Previous reviews have documented the
role of increased wall stress as a driving factor for ventricular remodeling[52, 53].Our previous
work has shown that early treatment to prevent adverse LV remodeling in the initial phase has
beneficial effects to extend the compensated state even when the treatment is discontinued[54].
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Conclusion:
Ventricular remodeling due to PO induced by abdominal aortic coarctation was
associated with hypertrophy, fibrosis, and altered chamber morphology after 14 days. These
changes in LV tissue properties were attenuated by selective COX-2 inhibition. Acute increase in
myocardial expression of H-type PGD synthase, as well as a decrease in L-type PGD synthase
were also associated with pressure overload induced cardiac remodeling. Long-term selective
inhibition of COX-2 uncouples the normal relationship between COX-1 and COX-2 derived
prostaglandins, promoting vasoconstriction and thrombosis and limiting chronic use. Our study
suggests there is a cardioprotective effects associated with acute inhibition of COX-2 with
pressure overload, a model of early hypertension. Short term administration of a COX-2
inhibition to newly diagnosed hypertension patients beginning anti hypertension therapy may
offer a clinical benefit. Alternatively, selective targeting of PGD isomerase(s) may lead to more
specific and effective therapeutic treatment without harmful side effects.
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AIM: 2
To investigate the efficacy of Prevention and intervention treatment
strategies of selective COX-2 inhibition on left ventricular maladaptive
cardiac remodeling induced by pressure overload.

Introduction:
Our work has demonstrated that at the 14 day time period pressure overload leads to significant
left ventricular hypertrophy, remodeling and fibrosis. These changes were significantly
attenuated with global COX-2 inhibition by Nimesulide treatment; establishing its therapeutic
potential in preventing pressure overload induced cardiac hypertrophy. The 14 day COX-2
inhibition study does not explore the progression of remodeling once the treatment is stopped
(Prevention) or the potential role of COX-2 inhibition in reversing already established cardiac
remodeling (Intervention).

Rationale:
Although acute COX-2 inhibition was found to be beneficial in attenuating maladaptive
structural and functional changes associated with pressure overload, further knowledge is
essential to assess the clinical significance of COX-2 inhibitors against maladaptive remodeling.
Taking into account the side effects of chronic selective COX-2 inhibition, limiting the long-term
use, the acute treatment is only clinically significant only when the beneficial effects persist even
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after the discontinuation of treatment. Also, in most clinical cases early detection of hypertension
is uncommon. Hence, it is essential for a therapeutic treatment to stop and/or potentially reverses
already established remolding. We designed the prevention treatment strategy study to
investigate the preservation of cardiac function for 14 days after discontinuation of acute
treatment (14 days) with a selective COX-2 inhibitor (Nimesulide) during the initial period of
hypertension in rats. This would help establish the long term beneficial effects of acute COX-2
inhibition on pressure overload induced cardiac remodeling. Intervention is a more clinically
useful treatment strategy is designed to assess the role of COX-2 inhibition at reversing already
established cardiac remodeling.

Experimental Approach:
The study was performed on 9 week old male Sprague Dawley rats. Pressure overload was
surgically induced by performing an abdominal aortic constriction as described earlier. The study
will include four groups (n=8/group) 1) Sham-operated group (SHAM) 2) Untreated pressureoverload group (PO) 3) Nimesulide (25mg/kg/day s.q.) prevention treated group (Prevention)
and 4) Nimesulide (25mg/kg/day s.q.) intervention treated group (Intervention).
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Figure 4: Study treatment strategies.

The prevention group involved initiation of Nimesulide treatment one day prior to the
surgical induction of hypertension and is continued till day 14. On day 14 the treatment was
stopped and the animals were allowed to progress under PO for another 14 days (Figure 4). For
the intervention group, treatment was initiated on day 14 post-induction of pressure overload and
was continued till day 28 when the ventricles show significant remodeling. On day 28, a
Scisense (Scisense Inc, Ontario, Canada) admittance catheter was used to determine various left
ventricular structure and functional parameters including ESP, EDP, EDV, LV mass, max DP/dt,
Tau coefficient, and EDPVR. LV tissue extracts were used for protein analysis by western
blotting to measure the levels of COX-2, H-PGD synthase and L-PGD synthase levels were
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measured using ELISA (Caymen Chemicals). Total myocardial levels of collagen were
determined using hydroxyproline assay.

Results:
Table 3: Structural and functional parameters of 28 day controls, PO, NIME prevention
and NIME intervention treated animals.

Parameters:
in vivo

Sham –

28-day

28 -day Nimesulide

28 –day Nimesulide

conductance

operated

untreated PO

– treated Prevention

treated Intervention

Body weight (gm) 363±6

353 ± 6

348 ± 2

361±9

LV Wt (mg)

792 ± 21

1010 ± 17*

898 ± 50

920±48*

LV/Bdy Wt Index

2.2± 0.04

2.9 ± 0.1*

2.6 ± 0.1*

2.5±0.1*

124 ± 8

163 ± 13 *

177 ± 6 *

144±9*

282 ± 20

185 ± 13 *

272 ± 25¥

233±27 ¥

200 ± 13

143 ± 10*

208 ± 11 ¥

205±16 ¥

8136±621

10560±472*

10672±226*

10479±800*

14±0.6

19±1.5*

17±1.7

16±0.7

catheter

Mean arterial
pressure (mmHg)
End diastolic
volume (l)
Stroke volume
(l)
Max dp/dt
(mmHg/s)
Tau (Galantz)
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Table 2: Comparison of Body Wt,LV structural and functional parameters in sham –operated (SHAM)
,untreated pressure overload (PO), PO+NIME prevention and intervention treatment strategies(n≤6 per

group). Values are reported as mean ± SEM. *p ≤ 0.05 vs. Sham. ¥ = p ≤ 0.05 vs. PO.

There was no significant change in body mass in any PO animals or treated animal, with
or without NIME as compared to sham. Mean arterial pressure (MAP) was found to be
significantly elevated by PO, as compared to SHAM, and was attenuated, but not fully reversed
by intervention (Table 3). The untreated PO group showed significant elevation in LV mass (best
indicated by a 24 % increase in the LV/bdy weight index), suggesting LV hypertrophy. This
increase in mass is associated with decrease in LV chamber size (approximately 34.5% reduction
in EDV compared to SHAM controls). Prevention treatment significantly prevented elevation of
LV mass which was maintained after discontinuation of treatment. Intervention treatment
successfully reversed already established increase in LV mass (Table 3).

Stroke volumes in PO animals were lower by approximately 29% as compared to SHAM
controls, indicating a loss of chamber size. The loss of stroke volume was significantly
attenuated by both Prevention and Intervention treatment demonstrated the potential for both
persistant changes and a reversal of ventricular remodeling. PO also significantly increased
myocardial contractility, as indicated by Max dP/dt, and loss of tissue compliance, indicated by
Tau. Prevention treatment significantly prevented the loss of tissue compliance without altering
myocardial contractility (see specific Aim 1 results) and these effects persisted 14 days post
discontinuation of treatment. Similarly stroke volume in Intervention animals was significantly
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higher than in PO animals, intervention treatment with Nimesulide. Intervention treatment
significantly reversed the loss of tissue compliance without effecting contractility (Table 3).

Figure 5: Analysis of total myocardial COX-2 Protein expression in the 28 day SHAM, PO,

Myocardial Total Collagen Content
(Hydroxyproline; ug/mg dry tissue)

NIME prevention and NIME intervention treated groups.

*

2.0

*
#

1.5

1.0

0.5

0.0
Sham

Untreated PO

Nime Prevention Nime Intervention

Figure 5: Analysis of total myocardial collagen expression in sham-operated (SHAM), Pressure
overloaded (untreated PO), Nimesulide treated prevention and Nimesulide treated intervention
groups (n≤7 per group). (* denotes p<0.05, Compared to sham, # denotes p<0.05, Compared to
untreated PO). Values are reported as mean ± SEM

The total collagen levels measured using the hydroxyproline assay showed a significant
elevation of total myocardial collagen in PO animals as compared to SHAM controls (Figure 5).
Prevention treatment blocked this fibrotic response (see specific Aim 1 results) and the beneficial
effects were still significant 14 days after discontinuation of treatment. Intervention treatment
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with failed to restore the elevated collagen levels. This indicates that once the initial remodeling
has already occurred the intervention treatment would only restore certain parameters like stroke
volume and Max dP/dt, without affecting other maladaptive changes in LV mass, EDV and total
collagen levels.

Discussion:
Our previous work demonstrated that at the 14 day time period animals with pressure
overload show significant maladaptive LV remodeling[55]. This includes increased LV mass
along with a reduction in LV chamber size. The heart also showed significant increase in total
collagen levels indicating fibrosis. Along with these structural changes, several functional
parameters such as loss of tissue compliance, increased contractility and reduced stroke volumes
were observed. Nimesulide treatment was found to be beneficial in attenuating these changes
when given for the whole study period of 14days. The prevention and intervention treatment
strategies were designed to study the efficacy of Nimesulide treatment on long term progression
of remodeling and its potency to reverse already established remodeling respectively. The
Prevention model is setup to explore the continuity of benefit afforded should PO persist after
COX-2 inhibition is stopped. It was demonstrated that the, attenuation of LV mass index is still
significant even 14 days after discontinuation of treatment. This suggests that early treatment
with selective COX-2 inhibitors could block initial maladaptive remodeling and these results are
still significant even after discontinuation of treatment. Along with attenuating structural
maladaptations, prevention treatment also helped retain compliance of LV tissue and increase
contractility leading to preservation of stroke volume and cardiac output. Prevention treatment
also helped attenuate LV fibrosis as indicated by maintenance of total collagen levels in LV
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tissue. These results suggest that a novel treatment strategy involving addition Nimesulide to the
normal anti-hypertensive treatment prescribed to patients recently diagnosed hypertension, could
prevent the maladaptive remodeling associated with hypertension without precipitating adverse
effects associated with chronic Nimesulide administration. The intervention treatment with
Nimesulide successfully reversed already established increase in LV mass index and loss of
chamber size. As evident from mean arterial pressure values, beneficial effects of Nimesulide
treatment were not due to lowering of blood pressure. Intervention treatment with Nimesulide
also showed significant reduction in already established loss of tissue compliance without
effecting contractility. Intervention treatment on the other hand failed to reverse established
fibrosis in the left vertical. Based on these results, acute treatment with Nimesulide can be
clinically significant in reversing pathological changes in certain parameters effecting cardiac
function such as elevation in LV mass and reduction in chamber size.

Significance:
The results of the prevention and intervention treatment has shown that acute treatment
with specific COX-2 inhibitors might be of great clinical significance in preventing and
reversing cardiac remodeling induced by pressure overload.
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AIM: 3
To investigate the efficacy of two treatment strategies of selective
Hematopoietic Prostaglandin D synthase inhibition on left ventricular
maladaptive cardiac remodeling induced by pressure overload.

Introduction:
Cyclooxygenase-2 catalyzes the conversion of arachidonic acid to prostaglandin H2.
Subsequently, all other prostaglandins are biosynthesized by the action of their specific synthases
from the common precursor prostaglandin H2. Various prostaglandins such as PGE2, PGF2 and
their specific receptors are being studied to evaluate their cardio-protective roles. Currently there
is no literature that evaluated the cardio-protective role of PGD2. Studies by Gupte et al showed
that the levels of PGD2 were the most elevated in a stressed myocardium as compared to other
prostaglandins[40]. Consistent with these findings, our previous studies (Aim 1) also
demonstrated that pressure-overload induced myocardial stress leads to significant up regulation
of H prostaglandin D synthase[42]. As previously mentioned, H-PGD synthase and L-PGD
synthase are the two specific synthases which catalyze the conversion of prostaglandin H2 to
Prostaglandin D2. In Aim 1, we demonstrated that attenuation of cardiac remodeling by
Nimesulide treatment was associated with a significant down regulation of myocardial H-PGD
synthase levels[42]. In addition to these findings PGJ2 the endogenous metabolite of PGD2 was
also associated with cardio-protective effects. The non-enzymatic downstream metabolite of
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PGJ2, 15- deoxy–PGJ2 is the endogenous ligand for peroxisome proliferator activator receptor
gamma (PPAR-).Studies showed that PPAR- receptor activation in pulmonary and renal
tissues leads to fibroblast proliferation collagen deposition and cytokine release[56, 57]. This
also suggests that PGD2 plays an essential role in mediating pressure overload induced cardiac
remodeling and the beneficial effects associated with Nimesulide treatment were due to
subsequent reduction in PGD2 levels. The potential cardio protective effects of selective blocking
of these synthases in order to reduce PGD2 expression are currently unknown. Thus we
hypothesized that H-PGD synthase inhibition may prove to be a more specific target to attenuate
cardiac remodeling as compared to global prostaglandin inhibition by COX-2 inhibitors.
Therefore we proposed this study to understand the effects of H-PGD synthase inhibition by
prevention and intervention treatments on pressure overload induced cardiac remodeling.

Rationale:
Chronic specific COX-2 inhibition is known to cause renal and cardiovascular
complications due to altered balance between the pro and anti-thrombotic actions of
thromboxanes and prostacyclins, respectively. Selective COX-2 inhibition leads to inhibition of
global prostaglandin synthesis through the inhibition of the common precursor PGH2. The
elevation of PGD2 levels in the stressed myocardium as demonstrated by Gupte et al and the
elevation of H-PGD synthase levels in hypertensive rats (AIM 1) as demonstrated in our study;
point towards PGD2 as an important mediator of pressure overload induced cardiac remodeling.
Specific H-PGD synthase inhibition would block the synthesis of Prostaglandin D without
effecting biosynthesis of any other prostaglandins. It is known that the side effects associated
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with chronic selective COX-2 inhibition are due to global prostaglandin inhibition. Specific
inhibition of prostaglandin D synthase could help elucidate the cardioprotective role of blocking
PGD2 synthesis on attenuating cardiac remodeling without the potential side effects associated
with COX-2 inhibition. Prevention treatment with specific H- PGD synthase inhibitors was
designed to evaluate the efficacy of H-PGD synthase inhibition in preventing cardiac remodeling
induced by pressure overload and the persistence of its effects after discontinuation of treatment.
The Intervention treatment strategy with H-PGD synthase inhibitor HQL 79 is designed to study
the efficacy of PGD2 inhibition on reversing already established remodeling.

Approach:
Five groups with 8 animals (Nine week old Sprague dawley rats) per group were used: 1.
Sham-operated group (SHAM); 2. Untreated pressure overload group (PO); 3. H-PGD synthase
inhibitor (HQL 79, Tocris BiosciencesTM) treated (10/mg/kg/day oral gavage) group 4.
Prevention HQL 79 treated PO group 5. Intervention HQL 79 treated PO group. Prevention
treatment group involves initiation of treatment with HQL 79 one day prior to induction of
pressure overload and continued till day 14 post surgery. Intervention treatment was initiated 14
days post induction of pressure overload and is continued till day 28. On day 28 various cardiac
structural and functional parameters like LV mass, EDV, ESV, ESP, Max DP/dt and Tau will be
assessed using the pressure volume conductance catheter. Total levels of extracellular collagen
are determined using hydroxyproline assay. HPLC analysis will be done to measure the levels of
prostaglandin (i.e, PGI, PGE, PGD).
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Results:

Table 4: Structural and functional parameters of 28 day controls, PO, HQL 79 prevention
and HQL 79 intervention treated animals.

Parameters:
in vivo

SHAM –

28-day

28 -day HQL 79

28 –day HQL 79

conductance

operated

untreated PO

treated Prevention

treated Intervention

Body weight (gm)

376±6

347 ± 5

356 ± 7

357±11

LV Wt (mg)

756 ± 17

989 ± 32*

795 ± 41¥

916±35*

LV/Bdy Wt Index

2.0± 0.04

2.8 ± 0.1*

2.2 ± 0.1¥

2.5±0.1*

124 ± 9

163 ± 8 *

152 ± 5 *

164±11

326 ± 20

231 ± 18 *

338 ± 30¥

317±20¥

Stroke volume (l) 152 ± 13

106 ± 10*

159 ± 9

151±18 ¥

8181±470

10369±860*

9274±520*

10560±591*

13±0.7

17±0.8*

14±0.5

18±1.8

catheter

Mean arterial
pressure (mmHg)
End diastolic
volume (l)

Max dp/dt
(mmHg/s)
Tau (Mirsky)

Table 3: Comparison of Body Wt, LV structural and functional parameters in sham –operated
(SHAM) ,untreated pressure overload (PO), PO+HQL prevention and intervention treatment.
strategies. Values are reported as mean ± SEM (n= 7 per group) *p ≤ 0.05 vs. Sham. ¥ = p ≤ 0.05
vs. PO.
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Compared to the SHAM controls, PO animals showed a 28.5% increase in LV/bdy wt
index and 30% decrease in end diastolic volume and stroke volume. Prevention treatment with
the specific H – PGD synthase inhibitor HQL 79, significantly attenuated the PO induced
increase in LV mass index, decrease in stroke volume and decrease in EDV. Intervention
treatment with HQL 79 significantly recessed the increase in LV mass index and loss of chamber
volume as indicated by end diastolic volume (Table 4).
Compared to SHAM controls, PO animals showed a 35% increase in MAP. Neither
prevention treatment nor the intervention treatment affected the PO-induced increase in MAP.
PO animals also showed a significant increase in maxdP/dt (contractility) and Tau (relaxation
coefficient) as compared to SHAM controls. The prevention treatment significantly prevented
the increase in Tau even 14 days after discontinuation of treatment. Whereas, intervention
treatment did not affect either Max dP/dt or Tau coefficients as compared to untreated PO
animals. Total collagen levels measured using hydroxyproline assay were markedly higher (30
%) in PO animals as compared to SHAM controls. In both HQL 79 prevention and intervention
treatment groups the collagen levels were found to be significantly attenuated as compared to the
PO groups (Figure 6).
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Figure 6: Analysis of total myocardial COX-2 Protein expression in the 28 day SHAM, PO,
HQL prevention and HQL intervention treated groups.

*

Myocardial Total Collagen Content
(Hydroxyproline; ug/mg dry tissue)

2.0

#

#

1.5

1.0

0.5

0.0
Sham

Untreated PO

HQL Prevention HQL Intervention

Figure 6: Analysis of total myocardial collagen expression in sham-operated, Pressure
overloaded, HQL treated prevention and HQL treated intervention groups. Values are reported as
mean ± SEM. n≤6 per group (* denotes p<0.05, Compared to sham, # denotes p<0.05, Compared
to untreated PO).

Discussion:
Our previous work demonstrated the efficacy of a selective COX-2 inhibitor in
attenuating the maladaptive remodeling induced by pressure overload[55]. Nimesulide treatment
has shown to have persistent cardio protective effects on preventing and reversing cardiac
remodeling, but failed to reverse already established fibrosis. COX-2 inhibition in the clinic was
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associated with renal and cardiovascular complications due to chronic global prostaglandin
inhibition[58]. Prevention treatment with HQL 79 significantly preserved cardiac structure as
evident from LV mass index and end diastolic volumes even after discontinuation of treatment.
Intervention treatment was successful in reversing already established structural changes
associated with pressure overload. These changes were not associated with the elevated MAP
due to pressure overload, suggesting the cardioprotective effects of HQL treatments were not due
to any anti hypertensive effect of drug treatment. Along with preservation of structure,
prevention treatment also maintained various functional parameters like stroke volume and tissue
compliance, even 14 days after the discontinuation of treatment. This suggests that acute early
treatment with HQL 79 might be beneficial in attenuating early remodeling response in pressure
overloaded rats. Intervention treatment failed to reverse loss of tissue compliance as evident from
the Tau values. Results from prevention and intervention treatments suggest that HQL 79
treatment is efficacious in both preventing and reversing already established fibrosis as evident
from the total myocardial collagen levels. HQL 79 treatment showed effects similar to COX-2
inhibition with Nimesulide on PO induced cardiac remodeling. This suggests that the myocardial
stress induced by pressure overload leads to elevated levels of prostaglandin D synthesis via
increased levels of its specific synthase, H-PGD synthase. These increased levels of
prostaglandin D2 might be driving the remodeling response through its specific receptors.

Conclusion
The prevention and intervention treatments with HQL 79 showed that selective blockade
of H-PGD synthase can prevent and reverse cardiovascular remodeling induced by pressure
overload. Our previous studies demonstrated that selective COX-2 inhibition can prevent and
reverse various structural and functional aspects of maladaptive remodeling. Taking into
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consideration the clinical failure of selective COX-2 inhibitors and their associated adverse
effects, H-PGD synthase inhibition seems to be a more selective treatment strategy as compared
to COX-2 inhibitors to prevent and/or reverse PO induced cardiovascular remodeling. Currently
there is limited literature on the role of prostaglandin receptors DP1 and DP2 on cardiac
remodeling. In order to better understand the therapeutic potential of H-PGD synthase inhibition
a complete understanding of the mechanistic pathways associated with DP1 and DP2 receptors
need to be elucidated.
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AIM: 4
To elucidate the role of DP1 and DP2 receptors on cytokine expression
and extracellular remodeling in Human cardiac fibroblasts.

Introduction:
Our in vivo studies demonstrated that cardiac remodeling induced by pressure overload
can be prevented using COX-2 selective inhibitor (Nimesulide) and selective prostaglandin D
synthase inhibitors (HQL 79). These findings suggest that pressure overload-induced cardiac
remodeling was mainly mediated via prostaglandin D receptors in myocardium. Previous studies
have demonstrated that prostaglandin D receptors (DP1 and DP2 receptors) are expressed in the
cardiac myocytes and fibroblasts[39]. The DP1 receptor is a G protein coupled receptor linked to
the cAMP increasing Gs and it is known to inhibit cytokine release and chemotaxis. In contrast,
the DP2 receptor is a GPCR coupled to Gi (decreases cAMP) that promotes cytokine release and
chemotaxis [39]. To date, little is known about the DP1 and DP2 receptors and their role in the
myocardium. 15 – d PGJ2 is the endogenous ligand for PPAR  receptors, which are associated
with fibrosis and heart failure.15-d PGJ2 has been shown to bind to DP2 receptors with higher
affinity than PPAR  receptors[39]. Our previous studies have shown that, Nimesulide treatment
is associated with down regulation of COX-2 enzyme expression in rat hearts (AIM 1). The role
of DP1 and DP2 receptors in regulating COX-2 expression or the downstream actions of PGD2 in
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the remodeling myocardium has yet to be elucidated. Our preliminary findings suggest thatPGD2
plays a vital role in cardiac remodeling via its receptors DP1 and DP2. This study was designed
to elucidate the specific roles of PGD2 activation of DP1 and DP2 receptors in modulating
maladaptive remodeling during the pathophysiological stress.
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AIM: 4-1
To investigate the dose dependent effects of PGD2 on Human cardiac
fibroblasts.
Rationale:
Our previous studies demonstrated that specific inhibition of H-PGD synthase using HQL
79, leads to significant attenuation of pressure overload induced cardiac fibrosis in rats. Cardiac
fibroblasts are solely responsible for collagen expression in the heart. To date, there have been
no studies performed to investigate the effects of PGD2 on human cardiac fibroblasts. In order to
evaluate the specific role of DP1 and DP2 receptors on cytokine expression and fibrosis it is
essential to characterize the dose dependent effects of PGD2 on cardiac fibroblasts.

Approach:
Human cardiac fibroblasts (HCF) were obtained from ScienecellTM (Carlsbad, CA). The
HCF cells were treated with a 2-log range of PGD2 doses 100nM, 1M, 10 M for 24 and 48 hrs
in order to determine the resulting changes in collagen transcription and COX-2 expression
respectively. COX-2 expression was measured using a cell based Elisa (R  D systems).
Analysis of collagen I and III mRNA expression was measured using qRT-PCR.

Results:
COX-2 enzyme expression, measured using a COX-2 cell based ELISA showed a
significant downregulation of COX-2 expression with all given doses of PGD2 (10-8, 10-7 and 1052
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M), as compared to untreated control (Figure 7). Collagen IA (COL1A) and IIIA (COL3A),

were measured by qPCR; mRNA expression was found to be un-altered with all given doses of
PGD2 as compared to untreated controls.

Figure 7: PGD2 dose response on COX-2 expression.

Figure 7: Comparison of COX-2 expression in control, different concentrations(PGD2 10-8 , 10-7 ,
10-6 M) treated HCF cells. Values are reported as mean ± SEM * = p<0.05 vs. control.

Discussion:
The downregulation of COX-2 expression observed during treatment of HCF cells with
PGD2 might be due to a feedback regulation via DP1 and/or DP2 receptor signaling. This effect
might also be mediated via or downstream 15-d PGJ2 acting via PPAR-or DP2 mediated
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signaling or without a receptor mediated pathway. COL1A and 3A mRNA levels were found to
be unaltered by PGD2 treatment. This suggests that PGD2 expression might not alter the
expression of COL1A and COL3A mRNA expression. Further studies are required to elucidate
the specific roles of DP1 and DP2 receptors on collagen expression and COX-2 expression in
order to better understand the role of PGD2 in cardiac remodeling.
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AIM: 4-2
Investigate the specific role of DP1 receptors on PGD2 mediated effects
in human cardiac fibroblasts.

Rationale:
Although it is known that PGD2 has two specific receptors DP1 and DP2, it is not clear
which of these receptors plays a role in pressure overload induced cardiac remodeling and
fibrosis. This study was designed to investigate the specific role of DP1 receptor activation in
altering COX-2 expression and collagen deposition using selective DP1 receptor activating (BW
245C, Cayman chemicals TM) and blocking (BWA868C, Cayman chemicals TM) compounds.
Previous studies have shown to have an IC50 of 250nM for BW245C [59, 60] and ki of 1.7nM for
BW848C [32, 33].

Approach:
Five treatment strategies were employed in order to assess the role of DP1 mediated
effects on cardiac fibroblasts:
1. HCF cells incubated with PGD2 (100 nM)
2. Treatment with DP1 receptor agonist (BW245C, 1M);
3. Co-incubation of PGD2 (100nM) with DP1 receptor agonist (BW245C, 1M);
4. Treatment with DP1 receptor blocker (BWA868C, 0.3M).
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5. Co-incubation of PGD2 (100nM) and DP1 Receptor blocker (BWA868C, 0.3M);
Appropriate vehicle controls were also included in the study. The cells were incubated
with the above mentioned treatment strategies for 24 and 48 hrs in order to elucidate collagen
mRNA expression and COX-2 expressions respectively. The receptor blockers were added 30
mins prior to the addition of agonists. COX-2 expression levels were assessed using the cell
based COX-2 Elisa assay previously mentioned. Changes in gene expression of collagen type I
and III was measured using multiplexed qRT-PCR.

Results:
Figure 8 : DP1 receptor mediated effects on COX-2 expression.

Cardiac Fibroblast Cox-2 Expression
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0.15

#

#

0.10

*

*

*

0.05

2
PG

D

8C

8C

+

W
A
86

A
86
W
B

W
B

B

24
5C

B

+

W

PG
D

2

24
5C

^7
10
2
D
PG

C

on
tr
ol

0.00

Figure 9 : Comparison of COX-2 expression in control, PGD2 treated HCF cells, DP1 receptor
agonist (BW245C), BW245C+PGD2 10-7, DP1 receptor blocker (BWA868C), BWA868C+
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PGD2 10-7. Values are reported as mean ± SEM. * = p<0.05 vs. control and # = p<0.05 vs.PGD2
10-7

Figure 9: DP1 receptor mediated effects on COL 1A mRNA expression.

Figure 10: Comparison of Collagen 1A mRNA expression in untreated control, PGD2 treated
HCF cells, DP1 receptor agonist (BW245C), DP1 receptor blocker (BWA868C), BWA868C+
PGD2 10-7. Values are reported as mean ± SEM.* = p<0.05 vs. control.
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As previously noted, COX-2 expression was significantly downregulated by 100nM
PGD2 treatment as compared to untreated controls (figure 8). Similar, significant downregulation
in COX-2 expression was observed when HCF cells were treated with the DP1 receptor agonist
BW245C (Figure 8). Co-incubation of HCF cells with DP1 receptor agonist and PGD2 showed
significant downregulation in COX-2 expression similar to the results observed with BW245C
treatment. Co-incubation of cells with DP1 receptor antagonist BW868C and PGD2 showed
similar attenuation of COX-2 down regulation by PGD2.
As seen previously, treatment with PGD2 did not affect the expression of COL1A in HCF
cells, as compared to the untreated controls (Figure 9). However, treatment with the DP1 receptor
agonist, BW245C, significantly elevated the mRNA expression of COL1A, as compared to the
controls. Treatment with DP1 receptor antagonist BWA868C did not alter COL1A mRNA
expression, Nor did co-incubation with PGD2 and BWA868C.
COL3A mRNA levels were also unaltered by PGD2 treatment, as compared to untreated
controls (Figure 10). Similar to the findings with COL1A, COL3A mRNA levels were
significantly elevated upon treatment with DP1 receptor agonist BWA245C, as compared to
untreated controls. Neither, treatment with DP1 receptor antagonist BW868c, or co-incubation of
BWA868C with PGD2, affected COL3A expression as compared to the untreated controls.
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Figure 10: DP1 receptor mediated effects on COL 3A mRNA expression.

Figure 11: Comparison of Collagen 3A mRNA expression in control, PGD2 treated HCF cells,
DP1 receptor agonist (BW245C), DP1 receptor blocker (BWA868C) and BWA868C+ PGD2 107. Values are reported as mean ± SEM. * = p<0.05 vs. control and # = p<0.05 vs.PGD2 10-7.

COL3A mRNA levels were also unaltered by PGD2 treatment, as compared to untreated
controls (Figure 10). Similar to the findings with COL1A, COL3A mRNA levels were
significantly elevated upon treatment with DP1 receptor agonist BWA245C, as compared to
untreated controls. Neither, treatment with DP1 receptor antagonist BW868c, or co-incubation of
BWA868C with PGD2, affected COL3A expression as compared to the untreated controls.
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Discussion:
Prostaglandins were previously known to have regulatory effects on upstream COX-2
expression [61]. Certain prostaglandins such as PGF2 and 15-d PGJ2 (a non-enzymatic
downstream product of PGD2) were previously shown to downregulate COX-2 enzyme
expression[61]. In the current study, COX-2 expression was downregulated by PGD2 at
nanomolar concentration in HCF cells. A similar downregulation was observed when HCF cells
were treated with DP1 receptor agonist and with co-incubation of PGD2 and
BWA245C.Furthermore, the blockade of PGD2 mediated COX-2 downregulation by DP1
receptor antagonist BWA868C. These results suggest that PGD2 functions to decrease COX-2
expression through the activation of the DP1 receptor. Although, the effects observed during
specific blockade of DP1 receptor might also be due to DP2 receptor activation by 15-J PGD2 the
non enzymatic downstream product of PGD2.which is known to have a higher affinity to DP2
receptor as compared to PPAR  receptor.
Our in vivo studies have shown that pressure overload leads to an elevation of total
myocardial collagen levels, and this was correlated with an elevation of H-PGD synthase protein
levels. Treatment with PGD2 on HCF cells did not alter the levels of collagen type 1A or 3A
mRNA levels. COL1A and COL3A mRNA expression was significantly elevated when HCF
cells were treated with DP1 specific receptor activator BW245c. Treatment with DP1 receptor
antagonist showed no change in either COL1A or COL3A mRNA expression. These results
indicate that DP1 receptor activation by PGD2 might be responsible for elevated total myocardial
collagen levels in rats post pressure overload.
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AIM: 4-3
To compare the effects of treatment of specific DP2 receptor agonist and
antagonist to PGD2 treatment in Human cardiac fibroblasts.

RATIONALE:
This study was designed to evaluate the role of DP2 receptors in the remodeling response
by cardiac fibroblasts using specific DP2 receptor agonizing (13, 14 dihydro-15-keto PGD2,
Cayman chemicals TM, Ki value 36 nM)[62, 63] and antagonizing peptides (BAYU3405, Cayman
Chemicals TM , IC50 of 100 nM)[64, 65].

Approach :
Five treatment strategies were used:
1. HCF cells incubated with PGD2 (100 nM)
2. Treatment with DP2 receptor agonist (13, 14 dihydro-15-keto PGD2, 1mM);
3. Co-incubation of PGD2 with DP2 receptor agonist (13, 14 dihydro-15-keto PGD2,
1mM);
4. Treatment with DP2 receptor blocker (BAYU3405, 1mM).
5. Co-incubation of PGD2 (100nM) and DP2 Receptor blocker (BAYU3405, 1mM);
Appropriate untreated and vehicle controls were also included in the study groups. The
cells were incubated with the above mentioned compounds for 24hrs for elucidate collagen
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mRNA expression and 48hrs to assess COX-2 expressions. The inhibitors were added 30 mins
prior to the addition of agonists. COX-2 expression levels were assessed using a cell based COX2 Elisa KIT (R and D SystemsTM). Gene expression analysis of Collagen 1A and 3A mRNA
expression was measured using multiplexed qRT-PCR.
Results:
Figure 11: DP2 receptor mediated effects on COX-2 expression.

Figure 12: Comparison of COX-2 expression in control, PGD2 treated HCF cells, DP2 receptor
agonist (13, 14 dihydro-15-keto PGD2), 13-14 keto PGD2 + PGD2 10-7, DP1 receptor blocker
(BAYU3405), BAYU3405+ PGD2 10-7.Values reported as mean ±SEM. * = p<0.05 vs. control
and # = p<0.05 vs. PGD2 10-7.
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Figure 12: DP2 receptor mediated effects on COL 1A mRNA expression.

Figure 13: Comparison of Collagen 1A mRNA expression in control, PGD2 treated HCF cells,
DP2 receptor agonist (13, 14 dihydro-15-keto PGD2), DP2 receptor blocker (BAYU3405),
BAYU3405+PGD2 10-7. Values reported as mean ±SEM. n ≥ 5 per group * = p<0.05 vs. control
and # = p<0.05 vs.PGD2 10-7.

Compared to controls, 100nM prostaglandin D2 treated cells shows significant down
regulation of COX-2 as seen before (Figure 11). Treatment with DP2 receptor agonist (13, 14dihydro-15-keto PGD2) also significantly down-regulated COX-2 protein expression, to levels,
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comparable to PGD2. Co-incubation with 13, 14-dihydro-15-keto PGD2 and PGD2 unexpectedly
attenuated COX-2 down-regulation by PGD2 alone to levels statistically equivalent to the
controls. Incubation of HCF cells with selective DP2 receptor blocker BAYU3405 also did not
significantly attenuate COX-2 expression as compared to controls. Co-incubation of HCF with
PGD2 and BAYU3405 significantly down regulated COX-2 expression, equivalent to PGD2
alone.
Treatment with PGD2 did not affect the expression of COL 1A in HCF cells as compared
to the untreated controls (Figure 12). Treatment with DP2 receptor activator 13, 14-dihydro-15keto PGD2 significantly elevated mRNA expression of COL 1A as compared to the controls.
Upon treatment with DP2 receptor antagonist BAYU3405, the COL 1A mRNA expression was
significantly higher than the controls and was also significantly lower than 13, 14 dihydro-15keto PGD2. Co-incubation with PGD2 and BAYU3405 significantly attenuated the PGD2
mediated down-regulation of COL 3A.
COL3A levels were unaltered by PGD2 treatment as compared to untreated controls
(Figure 13). COL3A mRNA levels were significantly down-regulated upon treatment with the
DP2 receptor agonist 13, 14 dihydro-15-keto-PGD2 as compared to untreated controls. Treatment
with DP2 receptor antagonist BAYU3405 did not alter COL3A expression but Co-incubation
with BAYU3405 and PGD2 significantly elevated COL3A mRNA expression.
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Figure 13: DP2 receptor mediated effects on COL 3A mRNA expression.

Figure 14: Comparison of Collagen 3A mRNA expression in control, PGD2 treated HCF cells,
DP2 receptor agonist (13, 14 dihydro-15-keto PGD2), DP2 receptor blocker (BAYU3405),
BAYU3405+ PGD2 10-7. Values reported as mean ±SEM. n ≥ 5 per group. * = p<0.05 vs.
control and # = p<0.05 vs. PGD2 10-7.
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Discussions:
COX-2 enzyme expression was significantly down regulated by selective DP2 agonism,
similar to treatment with PGD2 alone suggests this that activating of DP2 receptor leads to a
negative feedback to COX-2 expression. DP2 receptor antagonism had no effect on COX-2
expression which further supports the hypothesis of a negative feedback loop. Interestingly, coincubation with PGD2 and a DP2 receptor agonist attenuated the COX-2 expression downregulation by either treatment alone. This might be due to over stimulation of DP2 receptor by
PGD2, 13, 14-dihydro-15-keto PGD2 and 15–d PGJ2. As previously mentioned 15 – d PGJ2, the
non enzymatic downstream product of PGD2 is known to have higher affinity to DP2 receptor
than its endogenous receptor PPAR-HFC cells treated the DP2 antagonist, with no lone
activity on COX-2 expression, and PGD2 led to the same decrease in COX-2 expression as PGD2
alone. This might be due to the action of PGD2 on the uninhibited DP1 receptors.
The DP2 antagonist alone did not alter collagen expression but the combination of the
agonist and PGD2 counter the intuitively increased COL 3A expression. COL 3A levels on the
other hand were found to be significantly down regulated upon DP2 receptor activation. DP2
receptor antagonism does not alter COL3A mRNA expression. Co incubation with DP2 receptor
antagonist with PGD2 led to significant up regulation of COL3A mRNA expression. This,
transcriptional up-regulation could be due to inhibition of the down regulation of COL3A
expression associated with DP2 receptor activation leading to elevation of COL3A expression via
PGD2 mediated activation of DP1 receptors. COL1A is known to be of higher tensile strength as
compared to COL1A. Thus, ratio of levels of COL 1A to 3A plays a vital role in determining the
myocardial wall thickness and compliance. Our own data demonstrated that activation of DP1
receptors increased both COL1A and COL3A mRNA expression leading to fibrosis. We further
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showed that activation of DP2 receptors led to an increase in COL1A and decrease in COL3A
resulting in altered ratio between COL1A and COL3A. This could potentially lead to reduced
compliance and increased stiffness of the left ventricle as seen in ventricular fibrosis.
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Figure 15: Schematic diagram depicting role of COX-2 and PGD2 on maladaptive left ventricular
remodeling.
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SYNOPSIS:
Chronic hypertension has long been known to cause left ventricular remodeling which
progresses into dilated cardiomyopathy and finally resulting in heart failure[66]. Although
previous studies pointed towards inflammation[13,14,15] as the pathological driving force for
cardiac remodeling. The exact mechanistic pathway associated with pressure overload-induced
cardiac remodeling remains to be elucidated.
Numerous studies were done to evaluate the role of COX activity and inhibition on
cardiac remodeling in models of infarction and heart failure[23,24]. Our study sought to
understand the role of inflammatory regulator COX-2 in mediating pressure overload induced
left ventricular remodeling. The results demonstrated that COX-2 plays a vital role in mediating
the two main aspects of LV remodeling, ventricular hypertrophy and extracellular matrix
remodeling. In a whole animal model of PO, selective inhibition of COX-2 with Nimesulide
significantly prevented initial ventricular maladaptive remodeling in particular LV mass,
EDPVR, Tau etc (Figure 14). In this study, pressure overload induced cardiac remodeling was
associated with elevated H-PGD synthase, suggesting that PGD2 in particular, out of all the
molecules down-stream of COX-2 plays an important role in pressure overload-induced LV
remodeling. Chronic COX-2 inhibition was associated with renal and cardiovascular
complications during chronic use[25,26]. Therefore it was essential to establish a timeline for
COX-2 inhibitory benefit and to understand the potential long terms beneficial effects associated
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with the acute treatment with COX-2 inhibitors. Thus we examined both the long term benefit of
early intervention and the efficacy of allowing PO induced cardiac remodeling and then
inhibiting COX-2. In particular the preventative treatment strategy with Nimesulide was
designed to assess potential long term beneficial effects post acute treatment during initial stages
of remodeling. The results indicated that Nimesulide treatment successfully attenuated various
aspects of maladaptive remodeling and the beneficial effects were significant even after the
discontinuation of treatment. In order to understand the Nimesulide on potentially reversing
already established remodeling the intervention treatment strategy was designed. The results
from the intervention treatment with Nimesulide indicated that although certain function
parameters were reversed, other complications like fibrosis as indicated by total myocardial
collagen levels were not affected by intervention treatment with Nimesulide.
The downstream mechanistic pathway beyond COX-2 inhibition involved was not clearly
understood. The beneficial effects associated with Nimesulide might be through one or more of
its downstream prostaglandins. Previously reported studies and our results from COX-2
inhibition suggested a role for PGD2 in preventing pressure overload-induced LV remodeling[40,
42]. In particular, further prevention and intervention studies with an H-PGD synthase inhibitor
(HQL 79) significantly attenuated maladaptive post PO remodeling and these effects were
similar to selective inhibition of upstream COX-2 suggesting that beneficial effects associated
with COX-2 inhibition are mediated via PGD2.
It remained unclear that the particular receptor mediated changes in the cardiac
fibroblasts that were responsible for ventricular remodeling whose blockade would be of highest
potential for the therapeutic benefit, therefore the effects of specific agonists and antagonists of
DP1 and DP2 were assessed.
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Both DP1 and DP2 activation significantly down regulated HCF cell COX-2 expression,
corresponding to the down regulation observed with PGD2 treatment. mRNA expression of both
COL1A and COL3A upon selective DP1 receptor activation indicates that the DP1 receptor plays
a vital role in elevation of total collagen levels leading to fibrosis. . Specific DP2 receptor
activation on the other hand was shown to alter the balance of COL1A to COL3A in favor of
Col1A, this could lead to altered LV tissue properties including loss of compliance and relation
properties of the LV. These results indicate that the PO mediated fibrosis was possibly due to
elevated PGD2 levels which act via DP1 and DP2 receptors.
The selective COX-2 inhibition studies (AIM 1 and 2) demonstrated that acute COX-2
inhibitors treatment during the initial stages of remodeling might have significant clinical
therapeutic potential to prevent or reverse various LV structural and functional parameters
associated with hypertension induced cardiac remodeling. These result indicate that, Nimesulide
treatment can be incorporated into the usual anti hypertensive treatment regime for patients
diagnosed with hypertension, to attenuate early LV remolding, Nimesulide treatment can be later
discontinues after the hypertensive stress is brought under control. This strategy would help
prevent maladaptive remodeling in the early stages of hypertensive stress. The selective H-PGD
synthase inhibition study in rats and the In vitro assessment of PGD2 mediated effects of human
cardiac fibroblasts (AIM 4) suggest that PGD2 plays a vital role in mediating PO induced cardiac
remodeling. Thus, specific inhibition of H-PGD synthase and/ or Prostaglandin receptors might
prove to be novel therapeutic targets which could have profound clinical significance in
preventing and reversing maladaptive LV remolding induced by hypertension without
precipitating the adverse effects associated with global prostaglandin inhibition.
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